117 related articles for article (PubMed ID: 28339471)
21. Polymorphisms of the CYP1B1 gene and hepatocellular carcinoma risk in a Chinese population.
Liu F; Luo LM; Wei YG; Li B; Wang WT; Wen TF; Yang JY; Xu MQ; Yan LN
Gene; 2015 Jun; 564(1):14-20. PubMed ID: 25796598
[TBL] [Abstract][Full Text] [Related]
22. Hepatic resection associated with good survival for selected patients with intermediate and advanced-stage hepatocellular carcinoma.
Zhong JH; Ke Y; Gong WF; Xiang BD; Ma L; Ye XP; Peng T; Xie GS; Li LQ
Ann Surg; 2014 Aug; 260(2):329-40. PubMed ID: 24096763
[TBL] [Abstract][Full Text] [Related]
23. Polymorphisms of vascular endothelial growth factor on prognosis in hepatocellular carcinoma patients receiving transcatheter arterial chemoembolization treatment.
Song J; Wang LZ; Li X; Jiang TP; An TZ; Xu M; Wu XP; Zhou S
Genet Mol Res; 2014 Oct; 13(4):8946-53. PubMed ID: 25366785
[TBL] [Abstract][Full Text] [Related]
24. Genetic variants of SOS2, MAP2K1 and RASGRF2 in the RAS pathway genes predict survival of HBV-related hepatocellular carcinoma patients.
Lin Q; Qiu M; Wei X; Xiang Z; Zhou Z; Ji I; Liang X; Zhou X; Wen Q; Liu Y; Yu H
Arch Toxicol; 2023 Jun; 97(6):1599-1611. PubMed ID: 37029817
[TBL] [Abstract][Full Text] [Related]
25. Association between vascular endothelial growth factor gene polymorphisms and survival in hepatocellular carcinoma patients.
Kong SY; Park JW; Lee JA; Park JE; Park KW; Hong EK; Kim CM
Hepatology; 2007 Aug; 46(2):446-55. PubMed ID: 17659575
[TBL] [Abstract][Full Text] [Related]
26. [Relationship between IL6 -572G/C polymorphism and hepatocellular carcinoma in men].
Liu S; Qiu XQ; Zeng XY; Bai H; Bei CH; Yang Y
Zhonghua Gan Zang Bing Za Zhi; 2012 Jun; 20(6):463-7. PubMed ID: 23044206
[TBL] [Abstract][Full Text] [Related]
27. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
28. A genetic variant in the promoter of CD46 is associated with the risk and prognosis of hepatocellular carcinoma.
Liu F; Luo L; Liu Z; Wu S; Zhang W; Li Q; Peng Y; Wei Y; Li B
Mol Carcinog; 2020 Nov; 59(11):1243-1255. PubMed ID: 32869896
[TBL] [Abstract][Full Text] [Related]
29. Glutathione S-transferase P1 gene rs4147581 polymorphism predicts overall survival of patients with hepatocellular carcinoma: evidence from an enlarged study.
Wang Z; Qu K; Niu W; Lin T; Xu X; Huang Z; Liu S; Liu S; Chang H; Liu Y; Dong X; Liu C; Zhang Y
Tumour Biol; 2016 Jan; 37(1):943-52. PubMed ID: 26260272
[TBL] [Abstract][Full Text] [Related]
30. Role of cytokine gene polymorphisms on prognosis in hepatocellular carcinoma after radical surgery resection.
Pan D; Zeng X; Yu H; Yang Y; Bei C; Bai H; Qiu X
Gene; 2014 Jul; 544(1):32-40. PubMed ID: 24768182
[TBL] [Abstract][Full Text] [Related]
31. Prognostic impact of telomere maintenance gene polymorphisms on hepatocellular carcinoma patients with chronic hepatitis B.
Jung SW; Park NH; Shin JW; Park BR; Kim CJ; Lee JE; Shin ES; Kim JA; Chung YH
Hepatology; 2014 May; 59(5):1912-20. PubMed ID: 23907815
[TBL] [Abstract][Full Text] [Related]
32. Study on the DNA repair gene XRCC1 and XRCC3 polymorphism in prediction and prognosis of hepatocellular carcinoma risk.
Han X; Xing Q; Li Y; Sun J; Ji H; Huazheng P; Jun L
Hepatogastroenterology; 2012 Oct; 59(119):2285-9. PubMed ID: 22456434
[TBL] [Abstract][Full Text] [Related]
33. The association of lncRNA-HULC polymorphisms with hepatocellular cancer risk and prognosis.
Wang BG; Lv Z; Ding HX; Fang XX; Wen J; Xu Q; Yuan Y
Gene; 2018 Sep; 670():148-154. PubMed ID: 29803923
[TBL] [Abstract][Full Text] [Related]
34. Transarterial chemoembolization in hepatocellular carcinoma treatment: Barcelona clinic liver cancer staging system.
Han K; Kim JH
World J Gastroenterol; 2015 Sep; 21(36):10327-35. PubMed ID: 26420959
[TBL] [Abstract][Full Text] [Related]
35. Recipient C6 rs9200 genotype is associated with hepatocellular carcinoma recurrence after orthotopic liver transplantation in a Han Chinese population.
Wang Z; Liao J; Wu S; Li C; Fan J; Peng Z
Cancer Gene Ther; 2016 Jun; 23(6):157-61. PubMed ID: 27173880
[TBL] [Abstract][Full Text] [Related]
36. Up-regulation of long non-coding RNA Sox2ot promotes hepatocellular carcinoma cell metastasis and correlates with poor prognosis.
Shi XM; Teng F
Int J Clin Exp Pathol; 2015; 8(4):4008-14. PubMed ID: 26097588
[TBL] [Abstract][Full Text] [Related]
37. Predictors of long-term survival in hepatocellular carcinomas: A longitudinal follow-up of 108 patients with small tumors.
Chang HC; Lin YM; Yen AM; Chen SL; Wu WY; Chiu SY; Fann JC; Lin YS; Chen HH; Liao CS
Anticancer Res; 2013 Nov; 33(11):5171-8. PubMed ID: 24222166
[TBL] [Abstract][Full Text] [Related]
38. Aggressive therapeutic strategies improve the survival of hepatocellular carcinoma patients with performance status 1 or 2: a propensity score analysis.
Hsu CY; Liu PH; Lee YH; Hsia CY; Huang YH; Chiou YY; Tsai YJ; Nagaria TS; Huo TI
Ann Surg Oncol; 2015 Apr; 22(4):1324-31. PubMed ID: 25326394
[TBL] [Abstract][Full Text] [Related]
39. Genetic variants in de novo lipogenic pathway genes predict the prognosis of surgically-treated hepatocellular carcinoma.
Jiang H; Dai J; Huang X; Chen Y; Qu P; Li J; Yi C; Yang Y; Zhang K; Huang Q
Sci Rep; 2015 Mar; 5():9536. PubMed ID: 25826294
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA Gene Polymorphisms in Evaluating Therapeutic Efficacy After Transcatheter Arterial Chemoembolization for Primary Hepatocellular Carcinoma.
Qiu GP; Liu J
Genet Test Mol Biomarkers; 2016 Oct; 20(10):579-586. PubMed ID: 27525669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
